MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

59.71
-1.13
-1.86%
After Hours: 59.71 0 0.00% 16:41 10/18 EDT
OPEN
60.48
PREV CLOSE
60.84
HIGH
61.12
LOW
59.42
VOLUME
133.07K
TURNOVER
--
52 WEEK HIGH
106.80
52 WEEK LOW
57.15
MARKET CAP
1.18B
P/E (TTM)
19.38
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ENTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ENTA News

  • Is Enanta Pharmaceuticals's (NASDAQ:ENTA) Share Price Gain Of 145% Well Earned?
  • Simply Wall St..6d ago
  • The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
  • Benzinga.10/10 11:31
  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.10/09 16:55
  • New Data from Enantas Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay
  • Business Wire.10/03 12:30

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About ENTA

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
More

Webull offers Enanta Pharmaceuticals Inc (ENTA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.